Turning a common oncogene's metabolic grip on cancer cells into a fatal weakness
For all its persistence as an adversary, aggressive breast cancer carries a weakness of its own making. A University of Helsinki research group has been investigating where this weakness comes from and how it can be exploited. The key lies in a protein called MYC, one of the most intriguing molecules in all of cancer research.
Breast cancer's survival appears to be undermined by a single protein, MYC, which has been shown to drive overactive energy metabolism in aggressive tumors. A research team at the University of Helsinki has discovered that cells with high levels of MYC rely heavily on glutamine as their sole energy source, creating a vulnerability that can be exploited.
By targeting this metabolic pathway with a combination of drugs that inhibit energy production and block glutamine uptake, the researchers were able to significantly slow the growth of breast cancer in mice. While these findings mark a significant step forward in understanding the biology of MYC-driven cancers, the researchers caution that this is only the beginning of a long road to new treatments.
The results, based on cell cultures and rodent experiments, have not yet been tested in human patients, and the treatment may only be effective for those whose tumors have highly active MYC. The ultimate goal is to develop a single drug capable of killing cancer cells expressing MYC, simplifying treatment and making it more personalized.
Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
